Result of AGM

RNS Number : 2137O

Renalytix AI PLC

30 September 2019

 

Renalytix AI plc

("RenalytixAI" or the "Company")

Result of AGM

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces at its annual general meeting held earlier today, the following resolutions were passed on a show of hands with the table below summarising proxy votes:

	Resolution	Votes for*	Votes against	Votes withheld
1.	To receive the audited accounts of the Company	24,481,789	22	0
2.	To re-elect Julian Baines	24,481,789	22	0
3.	To re-elect Christopher Mills	20,570,985	3,910,826	0
4.	To re-elect Richard Evans	24,481,789	22	0
5.	To re-elect Fergus Fleming	24,481,789	22	0
6.	To elect Doctor Erik Lium	24,481,789	22	0
7.	To elect James McCullough	24,481,789	22	0
8.	To elect Barbara Murphy	24,481,811	0	0
9.	To re-appoint the auditors PKF Littlejohn LLP and authorise the Directors to fix their remuneration	24,481,789	22	0
10.	To authorise the directors to replace the existing authority to allot shares in the Company in connection with s551 of the Companies Act 2006	24,481,789	22	0
11.	To authorise the directors to allot Relevant Securities as if s561 of the Companies Act 2006 did not apply	23,769,147	702,664	10,000

*Any proxy appointments, which gave discretion to the Chairman have been included in the 'For' votes total.

For further information, please contact:

Renalytix AI plc	www.renalytixai.com
James McCullough, CEO	Via Walbrook PR
Stifel (Nominated Adviser & Joint Broker)	Tel: [phone]
Alex Price / Jonathan Senior / Ben Maddison
N+1 Singer (Joint Broker)		Tel: [phone]
Aubrey Powell / James White / George Tzimas (Corporate Finance) Tom Salvesen / Mia Gardner (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Lianne Cawthorne	Mob: [phone]

About Kidney Disease 

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.

 

END

 

 

RAGEASNEDDANEFF